Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study

Kolodziej,M.; Goetz,C.; Di Fazio,P.; Montalbano,R.; Ocker,M.; Strik,H.; Quint,K.

doi:10.3892/or.2015.4105

Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study

Authors:
- M. Kolodziej
- C. Goetz
- P. Di Fazio
- R. Montalbano
- M. Ocker
- H. Strik
- K. Quint
View Affiliations

Affiliations: Department of Neurosurgery, University Hospital Giessen, Giessen, Germany, Institute for Surgical Research, University of Marburg, Marburg, Germany, Department of Neurology, Thoracic and Vascular Surgery, University Hospital Marburg, Marburg, Germany
Published online on: July 3, 2015 https://doi.org/10.3892/or.2015.4105
Pages: 1549-1556

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non small-cell lung cancer and lymphomas. It targets CDK2, 7 and 9 preferentially, which are also overexpressed in glioblastoma. Τherefore, the biological effects of roscovitine in glioblastoma cell lines were investigated. Glioblastoma A172 and G28 cell lines were incubated with serial concentrations of roscovitine for 24-120 h. Proliferation was measured using the xCELLigence Real-Time Cell Analyzer, an impedance‑based cell viability system. Cell cycle distribution was assessed by flow cytometry and gene expression was quantified by quantitative RT-PCR and western blot analysis. Roscovitine exhibited a clear dose-dependent anti‑proliferative and pro‑apoptotic effect in the A172 cell line, while G28 cells showed a anti-proliferative effect only at 100 µM. The results of the flow cytometric (FACS) analysis revealed a dose-dependent increase of the G2/M and sub-G1 fractions in A172 cells, while G28 cells responded with an elevated sub-G1 fraction only at the highest concentration. Roscovitine led to a dose‑dependent decrease of transcripts of p53, CDK 7 and cyclins A and E and an increase of >4-fold of p21 in A172 cells. In G28 cells, a dose‑dependent induction of CDK2, p21 and cyclin D was observed between 10 and 50 µM roscovitine after 72 h, however, at the highest concentration of 100 µM, all investigated genes were downregulated. Roscovitine exerted clear dose-dependent anti-proliferative and pro-apoptotic effects in A172 cells and less distinct effects on G28 cells. In A172 cells, roscovitine led to G2/M arrest and induced apoptosis, an effect accompanied by induced p21 and a reduced expression of CDK2, 7 and 9 and cyclins A and E. These effects requre further studies on a larger scale to confirm whether roscovitine can be used as a therapeutic agent against glioblastoma.

View Figures

View References

1	Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics and biology of a grave matter. Genes Dev. 15:1311–1333. 2001. View Article : Google Scholar : PubMed/NCBI
2	Hengstschläger M, Hölzl G and Hengstschläger-Ottnad E: Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle. Oncogene. 18:843–848. 1999. View Article : Google Scholar : PubMed/NCBI
3	Schiffer D, Cavalla P, Migheli A, Chiò A, Giordana MT, Marino S and Attanasio A: Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett. 195:81–84. 1995. View Article : Google Scholar : PubMed/NCBI
4	Costello JF, Plass C, Arap W, Chapman VM, held WA, Berger MS, Su Huang HJ and Cavenee WK: Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 57:1250–1254. 1997.PubMed/NCBI
5	Dirks PB, Hubbard SL, Murakami M and Rutka JT: Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J Neuropathol Exp Neurol. 56:291–300. 1997. View Article : Google Scholar : PubMed/NCBI
6	Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G and James CD: Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res. 4:215–222. 1998.PubMed/NCBI
7	Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K and Louis DN: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol. 55:1026–1031. 1996. View Article : Google Scholar : PubMed/NCBI
8	Rollbrocker B, Waha A, Louis DN, Wiestler OD and von Deimling A: Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol. 92:70–74. 1996. View Article : Google Scholar : PubMed/NCBI
9	Srivenugopal KS and Ali-Osman F: Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells. Oncogene. 12:2029–2034. 1996.PubMed/NCBI
10	Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG and Moulinoux JP: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 243:527–536. 1997. View Article : Google Scholar : PubMed/NCBI
11	Schutte B, Nieland L, Van Engeland M, Henfling ME, Meijer L and Ramaekers FC: The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res. 236:4–15. 1997. View Article : Google Scholar : PubMed/NCBI
12	Nair BC, Vallabhaneni S, Tekmal RR and Vadlamudi RK: Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res. 13:R802011. View Article : Google Scholar : PubMed/NCBI
13	Pizarro JG, Folch J, Junyent F, Verdaguer E, Auladell C, Beas-Zarate C, Pallàs M and Camins A: Antiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuro-blastoma cells. Apoptosis. 16:536–550. 2011. View Article : Google Scholar : PubMed/NCBI
14	Arısan ED, Coker A and Palavan-Ünsal N: Polyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in HCT116 colon carcinoma cells. Amino Acids. 42:655–665. 2012. View Article : Google Scholar
15	Cho SJ, Kim YJ, Surh YJ, Kim BM and Lee SK: Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem. 286:19662–19671. 2011. View Article : Google Scholar : PubMed/NCBI
16	Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S and Melmed S: Targeting zebrafish and murine pituitary corti-cotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci USA. 108:8414–8419. 2011. View Article : Google Scholar
17	Coley HM, Safuwan NA, Chivers P, Papacharalbous E, Giannopoulos T, Butler-Manuel S, Madhuri K, Lovell DP and Crook T: The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. Br J Cancer. 106:482–489. 2012. View Article : Google Scholar : PubMed/NCBI
18	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wellwood J and Taylor K: Central nervous system prophylaxis in haematological malignancies. Intern Med J. 32:252–258. 2002. View Article : Google Scholar : PubMed/NCBI
20	Sallam H, Jimenez P, Song H, Vita M, Cedazo-Minguez A and Hassan M: Age-dependent pharmacokinetics and effect of rosco-vitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res. 58:32–37. 2008. View Article : Google Scholar : PubMed/NCBI
21	Yakisich JS, Sidén A, Idoyaga Vargas V, Eneroth P and Cruz M: Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine. Biochem Biophys Res Commun. 243:674–677. 1998. View Article : Google Scholar : PubMed/NCBI
22	McClue SJ and Stuart I: Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 36:561–570. 2008. View Article : Google Scholar
23	Dhavan R and Tsai LH: A decade of CDK5. Nat Rev Mol Cell Biol. 2:749–759. 2001. View Article : Google Scholar : PubMed/NCBI
24	Hassan M, Sallam H and Hassan Z: The role of pharmaco kinetics and pharmacodynamics in early drug development with reference to the cyclin-dependent kinase (Cdk) inhibitor-roscovitine. Sultan Qaboos Univ Med J. 11:165–178. 2011.PubMed/NCBI
25	Paprskárová M, Krystof V, Jorda R, Dzubák P, Hajdúch M, Wesierska-Gadek J and Strnad M: Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine. J Cell Biochem. 107:428–437. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wesierska-Gadek J, Borza A, Komina O and Maurer M: Impact of roscovitine, a selective CDK inhibitor, on cancer cells: Bi-functionality increases its therapeutic potential. Acta Biochim Pol. 56:495–501. 2009.PubMed/NCBI
27	Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, Lane DP, Hubank M, Powell JE, Wei W, et al: A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood. 105:4484–4491. 2005. View Article : Google Scholar : PubMed/NCBI
28	Slovackova J, Smarda J and Smardova J: Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53. Neoplasma. 59:606–612. 2012. View Article : Google Scholar : PubMed/NCBI
29	Lim YM, Yamasaki Y and Tsuda L: Ebi alleviates excessive growth signaling through multiple epigenetic functions in Drosophila. Genes Cells. 18:909–920. 2013. View Article : Google Scholar : PubMed/NCBI
30	Węsierska-Gądek J, Gritsch D, Zulehner N, Komina O and Maurer M: Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells. J Cell Biochem. 112:761–772. 2011. View Article : Google Scholar
31	Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T, et al: Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem. 280:31208–31219. 2005. View Article : Google Scholar : PubMed/NCBI
32	Whittaker SR, Walton MI, Garrett MD and Workman P: The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 64:262–272. 2004. View Article : Google Scholar : PubMed/NCBI
33	Bertoli C, Klier S, McGowan C, Wittenberg C and de Bruin RA: Chk1 inhibits e2F6 repressor function in response to replication stress to maintain cell-cycle transcription. Curr Biol. 23:1629–1637. 2013. View Article : Google Scholar : PubMed/NCBI
34	Fischer PM and Lane DP: inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr Med Chem. 7:1213–1245. 2000. View Article : Google Scholar : PubMed/NCBI
35	Weinberg RA: The retinoblastoma protein and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI
36	Morgan DO: Principles of CDK regulation. Nature. 374:131–134. 1995. View Article : Google Scholar : PubMed/NCBI
37	MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP and Green SR: Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65:5399–5407. 2005. View Article : Google Scholar : PubMed/NCBI
38	Erguven M, Bilir A, Yazihan N, Korkmaz S, Aktas E, Ovalioglu C, Dundar T and Seyithanoglu H: Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine. Oncol Lett. 3:200–208. 2012.PubMed/NCBI
39	Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD and Workman P: The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle. 6:3114–3131. 2007. View Article : Google Scholar : PubMed/NCBI
40	Murphy ÁC, Weyhenmeyer B, Noonan J, Kilbride SM, Schimansky S, Loh KP, Kögel D, Letai AG, Prehn JH and Murphy BM: Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis. 19:629–642. 2014. View Article : Google Scholar :
41	Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
42	Sato Y, Kurose A, Ogawa A, Ogasawara K, Traganos F, Darzynkiewicz Z and Sawai T: Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. Cancer Biol Ther. 8:452–457. 2009. View Article : Google Scholar : PubMed/NCBI
43	Akudugu J, Gäde G and Böhm L: Cytotoxicity of azadirachtin A in human glioblastoma cell lines. Life Sci. 68:1153–1160. 2001. View Article : Google Scholar : PubMed/NCBI
44	Zhang T, Jiang T, Zhang F, Li C, Zhou YA, Zhu YF and Li XF: Involvement of p21^Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells. Oncol Rep. 23:239–245. 2010. View Article : Google Scholar
45	Schmidt M and Fan z: Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells. Oncogene. 20:6164–6171. 2001. View Article : Google Scholar : PubMed/NCBI
46	Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 1:639–649. 2002.PubMed/NCBI
47	Neyns B, D'haeseleer M, Rogiers A, Van de Cauter J, Chaskis C, Michotte A and Strik H: The role of cytotoxic drugs in the treatment of central nervous system gliomas. Acta Neurol Belg. 110:1–14. 2010.PubMed/NCBI